MRMD MARIMED INC.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1522767 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.5%
TTM net income YoY14.4%
TTM EPS YoY20.0%
Revenue 3-yr CAGR4.8%
Net income 3-yr CAGR—
Margins
Gross margin35.4%
Operating margin-1.7%
Net margin-9.3%
FCF margin5.5%
EBITDA margin3.6%
Returns
ROE-31.6%
ROA-7.7%
ROIC (approx.)-1.8%
Asset turnover0.83x
Leverage & solvency
Liabilities / assets76.3%
Debt / equity1.95x
Current ratio0.90x
Interest coverage-0.34x
Cash quality & payout
Operating cash flow / net income-0.65x
Accruals ratio-12.7%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $159.83M | $157.71M |
| Cost of revenue | $101.94M | $95.10M |
| Gross profit | $57.88M | $62.61M |
| SG&A expense | $26.14M | $25.62M |
| Operating income | -$2.82M | $2.61M |
| Interest expense | $7.50M | $6.94M |
| Pretax income | -$10.86M | -$4.27M |
| Income tax | $3.59M | $8.16M |
| Net income | -$14.48M | -$12.47M |
| EBITDA | $5.29M | $10.52M |
| EPS (basic) | -0.04 | -0.03 |
| EPS (diluted) | -0.04 | -0.03 |
| Weighted avg. shares (diluted) | 390.13M | 379.15M |
| Balance sheet | ||
| Cash & equivalents | $8.88M | $7.28M |
| Short-term investments | — | $0 |
| Receivables | $9.11M | $8.74M |
| Inventory | $36.60M | $33.49M |
| Current assets | $59.29M | $53.51M |
| PP&E, net | $89.39M | $94.17M |
| Goodwill | $24.00M | $15.81M |
| Intangibles | $17.21M | $18.64M |
| Total assets | $202.56M | $206.99M |
| Current liabilities | $59.07M | $50.01M |
| Long-term debt | $76.04M | $78.19M |
| Total debt | $76.04M | $78.19M |
| Total liabilities | $137.83M | $129.44M |
| Shareholders' equity | $51.87M | $60.30M |
| Net debt | $67.16M | $70.91M |
| Shares outstanding | 396.91M | 381.48M |
| Cash flow statement | ||
| Operating cash flow | $7.70M | $6.79M |
| Capital expenditure | $1.17M | $11.96M |
| Free cash flow | $6.53M | -$5.17M |
| Investing cash flow | -$1.38M | -$17.13M |
| Financing cash flow | -$4.71M | $2.98M |
| Depreciation & amortization | $8.11M | $7.91M |
| Stock-based compensation | $1.86M | $1.05M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.